Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology

Proceedings of the National Academy of Sciences, Volume 122, Issue 43, October 2025. <br/>SignificanceThis study presents S-1117, an IgG-specific protease, as a promising therapeutic approach for the treatment of acetylcholine receptor-positive myasthenia gravis (AChR-MG). S-1117 was shown to efficiently cleave the Fcγ region of pathogenic …